

Summary statistics - quantitative results

(Groups: manufacturer of kit)

Filter: minimal size of the groups n = 5

EQA round: HS2/21 - Haemocoagulation Special

Deadline: 19.11.2021

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of the participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U _{AV} = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability													
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	
Set 1															
(479) Factor VIII					100							100	98	98%	
Samples and groups	[%]														
Sample A1		70,1	6,3	9,0	100	CVP	70,1	1,5	25%	52,5	87,7	100	98	98%	
(38) IL		68,3	8,5	13	15	0						15			
(94) Stago		74,6	6,9	9,2	10	0						10			
(149) Siemens (Dade, BN, Dimension)		70,8	5,3	7,4	47	0						47			
(179) Siemens		69,3	5,8	8,4	12	0						12			
(193) HYPHEN BioMed		66,3	11	16	11	0						11			
Other					5	0						5			
							1x 63, 1x 100, 3x 175								
(480) von Willebrand f. (activity)					27							27	27	100%	
Samples and groups	[%]														
Sample A1		30,7	3,2	10	27	CVP	30,7	1,5	30%	21,4	40	27	27	100%	
(38) IL		29,5	3,7	13	6	0						6			
(149) Siemens (Dade, BN, Dimension)		31,2	2,5	8,0	14	0						14			
(179) Siemens		31,8	2,5	7,9	6	0						6			
Other					1	0						1			
							1x 0								
(481) von Willebrand f. (antigen)					28							28	27	96%	
Samples and groups	[%]														
Sample A1		47,1	3,7	7,8	28	CVP	47,1	1,7	20%	37,6	56,6	28	27	96%	
(38) IL		49,0	1,6	3,2	7	0						7			
(149) Siemens (Dade, BN, Dimension)		45,4	3,7	8,1	10	0						10			
(179) Siemens		45,6	1,4	3,1	6	0						6			
Other					5	0						5			
							1x 0, 1x 15, 3x 94								
Set 2															
(482) Factor IX					41							41	40	98%	
Samples and groups	[%]														
Sample A2		120	9,3	7,7	41	CVP	120	3,6	25%	90	150	41	40	98%	
(38) IL		112	11	9,4	8	0						8			
(149) Siemens (Dade, BN, Dimension)		122	5,6	4,6	16	0						16			
(179) Siemens		119	9,9	8,3	8	0						8			
(193) HYPHEN BioMed		127	7,6	5,9	5	0						5			
Other					4	0						4			
							4x 94								
(483) Factor XI					28							28	28	100%	
Samples and groups	[%]														
Sample A2		109	7,2	6,7	28	CVP	109	3,3	25%	81,7	137	28	28	100%	
(38) IL		103	7,9	7,6	6	0						6			
(149) Siemens (Dade, BN, Dimension)		108	6,7	6,2	12	0						12			
Other					10	0						10			
							2x 94, 4x 179, 4x 193								
(484) Factor XII					36							36	33	92%	
Samples and groups	[%]														
Sample A2		50,8	7,5	15	36	CVP	50,8	3,1	25%	38,1	63,5	36	33	92%	
(38) IL		55,9	8,4	15	6	0						6			
(149) Siemens (Dade, BN, Dimension)		49,1	7,7	16	15	0						15			
(179) Siemens		48,3	7,6	16	8	0						8			
Other					7	0						7			
							3x 94, 4x 193								
Set 3															
(485) Protein C					85							85	82	96%	
Samples and groups	[%]														
Sample A3		46,9	2,4	5,1	85	CVP	46,9	0,64	20%	37,5	56,3	85	82	96%	
(38) IL		45,7	2,6	5,6	15	0						15			
(94) Stago		52,5	8,2	16	6	0						6			
(149) Siemens (Dade, BN, Dimension)		46,8	2,3	4,9	37	0						37			
(179) Siemens		48,7	2,0	4,2	12	0						12			
(193) HYPHEN BioMed		46,3	2,5	5,4	13	0						13			
Other					2	0						2			
							1x 63, 1x 102								

Summary statistics - quantitative results

(Groups: manufacturer of kit)

Filter: minimal size of the groups n = 5

EQA round: HS2/21 - Haemocoagulation Special

Deadline: 19.11.2021

Test	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability						N _{eva}	N _{suc}	S _{rel}
							AV	U _{AV}	D _{max}	LL	UL				
(486) Protein S					79								79	79	100%
Samples and groups	[%]														
Sample A3		104	9,6	9,2	79		CVP	104	2,7	30%	72,8	136	79	79	100%
(38) IL		105	11	11	12	0							12		
(94) Stago		106	4,3	4,1	10	0							10		
(149) Siemens (Dade, BN, Dimension)		103	8,9	8,6	33	0							33		
(179) Siemens		104	4,9	4,7	10	0							10		
(193) HYPHEN BioMed		108	15	14	12	0							12		
Other					2	0							2		
								1x 63, 1x 184							
(487) ProC Global (norm. ratio)					29								29	28	97%
Samples and groups	[-]														
Sample A3		0,548	0,062	11	29		CVP	0,548	0,028	25%	0,411	0,685	29	28	97%
(149) Siemens (Dade, BN, Dimension)		0,547	0,066	12	27	0							27		
Other					2	0							2		
								1x 63, 1x 179							
Set 4															
(491) Factor II					32								32	32	100%
Samples and groups	[%]														
Sample A4		58,9	4,2	7,1	32		CVP	58,9	1,8	25%	44,1	73,7	32	32	100%
(38) IL		55,6	0,67	1,2	5	0							5		
(149) Siemens (Dade, BN, Dimension)		58,6	4,2	7,2	14	0							14		
(179) Siemens		59,1	2,4	4,0	6	0							6		
Other					7	0							7		
								1x 63, 3x 94, 1x 100, 2x 193							
(492) Factor V					34								34	33	97%
Samples and groups	[%]														
Sample A4		69,9	4,9	7,0	34		CVP	69,9	2,1	25%	52,4	87,4	34	33	97%
(38) IL		66,1	2,9	4,4	5	0							5		
(94) Stago		69,0	4,4	6,4	6	0							6		
(149) Siemens (Dade, BN, Dimension)		72,2	3,3	4,6	14	0							14		
(179) Siemens		70,7	7,9	11	7	0							7		
Other					2	0							2		
								1x 63, 1x 100							
(493) Factor VII					37								37	36	97%
Samples and groups	[%]														
Sample A4		58,5	5,6	9,6	37		CVP	58,5	2,3	25%	43,8	73,2	37	36	97%
(38) IL		50,7	1,6	3,2	5	0							5		
(149) Siemens (Dade, BN, Dimension)		59,7	5,4	9,0	16	0							16		
(179) Siemens		57,8	5,9	10	8	0							8		
Other					8	0							8		
								1x 63, 3x 94, 1x 100, 1x 159, 2x 193							
(494) Factor X					30								30	30	100%
Samples and groups	[%]														
Sample A4		54,5	5,2	9,5	30		CVP	54,5	2,3	25%	40,8	68,2	30	30	100%
(38) IL		47,3	3,6	7,5	5	0							5		
(149) Siemens (Dade, BN, Dimension)		56,3	4,1	7,3	14	0							14		
(179) Siemens		52,5	4,8	9,2	5	0							5		
Other					6	0							6		
								1x 63, 3x 94, 2x 193							

st_kn_p

End of report

Printed: 01.12.2021